Current advances in targeted therapies for metastatic gastric cancer: improving patient care

Current advances in targeted therapies for metastatic gastric cancer: improving patient care

Author Aguiar, Pedro Nazareth, Jr. Autor UNIFESP Google Scholar
Muniz, Thiago Pimentel Autor UNIFESP Google Scholar
Miranda, Raelson Rodrigues Autor UNIFESP Google Scholar
Tadokoro, Hakaru Autor UNIFESP Google Scholar
Forones, Nora Manoukian Autor UNIFESP Google Scholar
Monteiro, Ines-de-Paula Google Scholar
Castelo-Branco, Pedro Google Scholar
Janjigian, Yelena Y. Google Scholar
de Mello, Ramon Andrade Google Scholar
Abstract In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous

therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.
Keywords Current Advances
Gastric Cancer
Gastric Cancer Therapy
Patient Care
Targeted TherapyAdvanced Esophagogastric Cancer
Multicenter Phase-Ii
Gastroesophageal Junction Cancer
Endothelial Growth-Factor
1st-Line Treatment
Randomized Phase-2
Plus Paclitaxel
Language English
Sponsor Pierre-Fabre
Date 2016
Published in Future Oncology. London, v. 12, n. 6, p. 839-854, 2016.
ISSN 1479-6694 (Sherpa/Romeo, impact factor)
Publisher Future medicine ltd
Extent 839-854
Access rights Closed access
Type Revisão
Web of Science ID WOS:000371064800012

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account